# Genotype-directed Neoadjuvant Chemoradiation for Rectal Carcinoma

> **NCT00682786** · PHASE2 · COMPLETED · sponsor: **Washington University School of Medicine** · enrollment: 135 (actual)

## Conditions studied

- Rectal Carcinoma

## Interventions

- **DRUG:** 5FU
- **RADIATION:** Radiation
- **PROCEDURE:** Surgery of resectable lesions
- **DRUG:** Irinotecan

## Key facts

- **NCT ID:** NCT00682786
- **Lead sponsor:** Washington University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-10
- **Primary completion:** 2008-12
- **Final completion:** 2010-08
- **Target enrollment:** 135 (ACTUAL)
- **Last updated:** 2017-10-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00682786

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00682786, "Genotype-directed Neoadjuvant Chemoradiation for Rectal Carcinoma". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00682786. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*